Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation |

When de-extinction startup Colossal Biosciences revealed last year that it was attempting to “resurrect” the dire wolf from genetic material found in fossils, we argued…

Colossal Foundation and University of Tasmania Partner to Combat Devil Facial Tumour Disease with Vaccines and Gene Editing

The collaboration leverages Colossal’s marsupial de-extinction and conservation biotechnology platform to save the Tasmanian devil from a contagious cancer that has driven 80% population declines…

Colossal Labs will release the sounds of dire wolves howling 'later this year,' founder says |

Jun 4, 2025 View From the Top by Raj Verma CEO SingleStore There’s an issue in the world of databases that’s slowing the progress of…